Associated Papers
Genetic and clinical factors associated with the metabolism of valproic acid in post-neurosurgery patients.
Cai X et al.
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2025
Insight into the structure, oligomerization, and the role in drug resistance of human UDP-glucuronosyltransferases.
Xue J et al.
Archives of Toxicology, 2025
Distribution pattern of UGT1A6 and UGT2B7 gene polymorphism and its impact on the pharmacokinetics of valproic acid and carbamazepine: Prospective genetic association study conducted in Pakistani patients with epilepsy.
Saleh Faisal M et al.
Gene, 2024
Effects of UGT1A, CYP2C9/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients.
Zheng XX et al.
Pharmacogenomics, 2023
Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: Exploratory analysis of the effects of clinical factors and gene variants.
Liu Y et al.
Basic & Clinical Pharmacology & Toxicology, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Heersche N et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
UGT2B7 gene polymorphism and linkage disequilibrium in pediatric epileptic patients and their influence on sodium valproate monotherapy: A cohort study.
Adiga S et al.
Frontiers in Pharmacology, 2022
Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation.
Wei Y et al.
Frontiers in Pharmacology, 2022
The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis.
Na Takuathung M et al.
Clinical Pharmacokinetics, 2021
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.
Iannaccone T et al.
Pharmaceuticals (basel, Switzerland), 2021
Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies.
Garcia-Rosa S et al.
Current Neuropharmacology, 2021
Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2021
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.
Cacabelos R
International Journal of Molecular Sciences, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Identification of Characteristic Genomic Markers in Human Hepatoma HuH-7 and Huh7.5.1-8 Cell Lines.
Kawamoto M et al.
Frontiers in Genetics, 2020
Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy.
Xu ZY et al.
Frontiers in Pediatrics, 2020
The UGTome: The expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism.
Hu DG et al.
Pharmacology & Therapeutics, 2019
Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects.
Zhu Q et al.
Frontiers in Pharmacology, 2019
Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients.
Kiang TKL et al.
Clinical Drug Investigation, 2018
Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors.
Xu S et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2018
Content and Activities of UGT2B7 in Human Liver In Vitro and Predicted In Vivo: A Bottom-Up Approach.
Xu C et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Lu Q et al.
Medicine, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018
Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.
Wang P et al.
European Journal of Clinical Pharmacology, 2018
Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C et al.
Biological & Pharmaceutical Bulletin, 2018
Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Sun Y et al.
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2017
The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ et al.
Acta Pharmacologica Sinica, 2017
Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity.
Yuan LM et al.
Scientific Reports, 2016
Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.
Du Z et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2016
Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine.
Wang Q et al.
Therapeutic Drug Monitoring, 2016
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.
Medhasi S et al.
Neuropsychiatric Disease and Treatment, 2016
The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients.
Sun YX et al.
Epilepsy Research, 2015
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.
Claudio-Campos K et al.
Drug Metabolism and Personalized Therapy, 2015
Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity.
Yuan L et al.
Biochemical Pharmacology, 2015
Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.
Xie XC et al.
Acta Pharmacologica Sinica, 2015
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M et al.
Cancer Chemotherapy and Pharmacology, 2015
[Features of clinical phenotype and genotype in Alport syndrome: a monocentric study].
Sun L et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics, 2015
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.
Swart M et al.
Frontiers in Genetics, 2015
Genome-wide detection of allelic gene expression in hepatocellular carcinoma cells using a human exome SNP chip.
Park YM et al.
Gene, 2014
Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.
Wang TH et al.
The Aaps Journal, 2014
Comprehensive variant screening of the UGT gene family.
Kim JY et al.
Yonsei Medical Journal, 2014
Effect of UGT2B7 genetic variants on serum valproic acid concentration.
Ma H et al.
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences, 2013
Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.
Guo D et al.
European Journal of Clinical Pharmacology, 2013
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Li J et al.
Pharmacogenomics, 2012
Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen.
Wang H et al.
Biochemical Pharmacology, 2011
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM et al.
The American Journal of Cardiology, 2010
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.
Fujita K et al.
Cancer Chemotherapy and Pharmacology, 2010